Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06302712
Other study ID # TIIP
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date November 30, 2024

Study information

Verified date March 2024
Source International Islamic University Malaysia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current study aims to determine the effectiveness of the first culturally adapted Traditional Islamically Integrated Psychotherapy (TIIP) for Muslims with OCD in Pakistan along with the module effectiveness in reducing OCD symptoms with comorbidities like anxiety, depression, stress, thought control, thought-action fusion, and enhancing the spiritual quality of life of participants.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date November 30, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - The client diagnosed with OCD according to DSM-5-TR. - The minimum score on Y-BOCS is 08 (i.e., indicating moderate level of symptoms) - The age range is from 18 to 40 years - The client has a minimum of eight years of formal education Exclusion Criteria: - The client is having a comorbid diagnosis of severe psychiatric illness (e.g., psychotic disorders, personality disorder, substance use disorder, neurocognitive disorder) - The client is having a comorbidity of chronic physical illness - The client refused to sign the informed consent form, - The client has experience undergoing manualized faith-based CBT

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Traditional Islamically Integrated Psychotherapy
Traditional Islamically Integrated Psychotherapy for OCD. We will be using the culturally adapted module of TIIP that is translated into the Urdu language for Pakistan Muslims with OCD. The treatment module is mainly based on four domains Nafs (Behavior), Ihsas (Emotions), Aql (Thought), and Ruh (Spirituality). The session will be conducted in an individual format, with eight sessions, and the intervention will be conducted by a certified therapist in TIIP.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
International Islamic University Malaysia Foundation University Islamabad

Outcome

Type Measure Description Time frame Safety issue
Primary Yale Brown Obsessive Compulsive Scale Yale Brown Obsessive Compulsive is a 10-item self-report scale developed to assess the severity of both obsession and compulsion.
Minimum score is 0 and maximum score is 40. The higher the scores mean the worst outcome.
Cut-off Scores:
0-7 (sub-clinical) 8-15 (Mild) 16-23 (Moderate) 24-31 (severe) 32-40 (Extrerme)
8 weeks
Secondary Depression, Stress, Anxiety Depression, Stress, Anxiety is measured through scale
Minimum score is 0 and maximum score is 42. The higher the scores mean the worst outcome.
Cut-off scores for each subscales.
Stress:
0-10 (normal) 11-18 (mild) 19-26 (moderate) 27-34 (severe) 35-42 (Extremely severe)
Anxiety:
0-6 (normal) 7-9 (mild) 10-14 (moderate) 15-19 (severe) 20-42 (Extremely severe)
Depression:
0-9 (normal) 10-12 (mild) 13-20 (moderate) 21-27 (severe) 28-42 (Extremely Severe)
8 Weeks.
Secondary Thought Action Fusion Thought Action Fusion is measured with the help of Thought Action Fusion Scale
Minimum score is 0 and maximum score is 76. The higher the scores mean the worst outcome.
8 weeks
Secondary Thought Control Thought Control is measured with the help of Thought Control Questionnaire
Minimum score is 30 and maximum score is 120. The higher the scores mean the worst outcome.
8 weeks
Secondary Spiritual Quality Spiritual Quality is measured with the help of World Health Organization Quality of Life Spirituality, Religiousness and Personal Beliefs Scale
Minimum score is 9 and maximum score is 45. The higher the scores mean the worst outcome.
8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3